Regeneron Pharmaceut

REGN
Real-time BATS EXCHANGE - 11/20 04:00:00 pm
344.145USD
-0.07%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2018 2019 (e)
Sales 6 711 7 782
EBITDA 3 110 3 440
Operating profit (EBIT) 2 534 2 283
Pre-Tax Profit (EBT) 2 554 2 360
Net income 2 444 2 002
P/E ratio 17,5x 19,7x
EPS ( $ ) 21,3 17,5
Dividend per Share ( $ ) - -
Yield - -
Reference price ( $ ) 373,500 344,460
Announcement Date 02/06/2019
11:30am
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2018 2019 (e)
Debt - -
Finance 2 101 5 371
Operating income (EBITDA) 3 110 3 440
Leverage
(Debt/EBITDA)
- -
Capital Expenditure 383 418
Free Cash Flow (FCF) 1 812 2 306
Book Value Per Share (BVPS) ( $ ) 76,3 111
Cash Flow per Share ( $ ) 19,1 29,2
Announcement Date 02/06/2019
11:30am
-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 37 657 M $ -
Entreprise Value (EV) 32 286 M $ 30 718 M $
Valuation 2019e 2020e
P/E ratio (Price / EPS) 19,7x 15,7x
Capitalization / Revenue 4,84x 4,51x
EV / Revenue 4,15x 3,87x
EV / EBITDA 9,38x 8,40x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,12x 2,45x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) 29,3% 34,7%
Operating Leverage (Delta EBIT / Delta Sales) - 3,71x
Net Margin (Net Profit / Revenue) 25,7% 30,2%
ROA (Net Profit / Asset) 18,8% 17,8%
ROE (Net Profit / Equities) 24,0% 22,5%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   5,37% 5,34%
Cash Flow / Sales 41,1% 36,1%
Capital Intensity (Assets / Sales) 1,37x 1,70x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
BNA & Dividende